Worth reading
60In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
20000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status of the 22nd Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
Who receives how much
Number of shares delivered during the month: 20,000 new shares. Treasury shares transferred: 0 shares
EVO FUND (the allottee of these Stock Acquisition Rights issued on 13 May 2026)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
Exercise ratio under the exercise restriction: 0.0% (20,000 shares delivered, aggregated across all series / 45,593,560 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise price during the target month: ¥27.00 or ¥28.00. The rights include an exercise price adjustment clause, but the floor for the adjustment is Not disclosed
Number of Stock Acquisition Rights
Total issued: 210,000 units. Unexercised as of the end of the month preceding the target month: 104,660 units; unexercised as of the end of the target month: 104,460 units
Procedures under the Corporate Code of Conduct
Reported compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
Disclosed on 27 April 2026: Issuance through a third-party allotment of the 22nd Series Stock Acquisition Rights (with an exercise price adjustment clause) and the 2nd Series Unsecured Bonds (private placement) (prior disclosure referenced by this document)
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status of the 22nd Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 20,000 new shares. Treasury shares transferred: 0 shares |
| Intended allottee | EVO FUND (the allottee of these Stock Acquisition Rights issued on 13 May 2026) |
| Dilution Rate | Exercise ratio under the exercise restriction: 0.0% (20,000 shares delivered, aggregated across all series / 45,593,560 listed shares as of the payment date for the issuance) |
| Total number of issued shares | 56,127,560 shares (as of the end of the month preceding the target month) → Not disclosed |
| Exercise price | Exercise price during the target month: ¥27.00 or ¥28.00. The rights include an exercise price adjustment clause, but the floor for the adjustment is Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 210,000 units. Unexercised as of the end of the month preceding the target month: 104,660 units; unexercised as of the end of the target month: 104,460 units |
| Procedures under the Corporate Code of Conduct | Reported compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Disclosed on 27 April 2026: Issuance through a third-party allotment of the 22nd Series Stock Acquisition Rights (with an exercise price adjustment clause) and the 2nd Series Unsecured Bonds (private placement) (prior disclosure referenced by this document) |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of the 22nd Series Stock Acquisition Rights in October 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.